JR-AB2-011 NEW
| Price | $87 | $213 | $363 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: JR-AB2-011 | CAS No.: 2411853-34-2 |
| Purity: 98.87% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | JR-AB2-011 |
| Description | JR-AB2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM. It inhibits mTORC2 activity by blocking Rictor-mTOR association (Ki: 0.19 μM) and exhibits cytotoxicity in glioblastoma [1]. |
| In vitro | JR-AB2-011 (1 μM; 24 hours) shows good anti-GBM properties, blocks mTORC2 signaling and Rictor association with mTOR [1]. JR-AB2-011 (0.5-2 μM; 48 hours) displays the least toxicity to normal neurons with no significant cytotoxic effects for concentrations up to 10 mM compared to CID613034 [1]. Apoptosis Analysis [1] Cell Line: U87 GBM cells; LN229 GBM cells Concentration: 1 μM Incubation Time: 24 hours Result: Had good anti-GBM properties and blocked mTORC2 signaling and Rictor association with mTOR. Cell Cytotoxicity Assay [1] Cell Line: Normal mature human neurons Concentration: 0.5, 1, 2 μM Incubation Time: 48 hours Result: Displayed the least toxicity to normal neurons with no significant cytotoxic effects for concentrations up to 10 mM. |
| In vivo | Mice administered JR-AB2-011 through intraperitoneal injection at doses of 4 mg/kg or 20 mg/kg daily for 10 days exhibited significant suppression of tumor growth compared to those treated with a vehicle control. Specifically, the lower dose achieved a 74% reduction in tumor growth rate with a 10-day delay in tumor progression, while the higher dose resulted in an 80% reduction and a 12-day delay. This study utilized female C.B.-17-scid mice implanted with LN229 cells, demonstrating that JR-AB2-011 is potent in inhibiting tumor growth at both tested concentrations. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 61.5 mg/mL (154.41 mM) |
| Keywords | JRAB2011 | JR-AB2-011 | JR-AB-2-011 | JR AB2 011 |
| Inhibitors Related | α-Hydroxyglutaric Acid Lithium | L-Leucine | Capivasertib | Sapanisertib | Everolimus | Bimiralisib | Salidroside | Tacrolimus | GDC0084 | TMBIM6 antagonist-1 | Dihydromyricetin | Rapamycin |
| Related Compound Libraries | Bioactive Compound Library | Anti-Diabetic Compound Library | Kinase Inhibitor Library | Glutamine Metabolism Compound Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Oxidation-Reduction Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $48.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1190.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $100.00/1KG |
Chongqing Chemdad Co.,Ltd
|
2019-06-27 | ||
| $87.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY